AHCO 📈 Adapthealth - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US00653Q1022
AHCO: Medical Equipment, Supplies, Sleep Therapy, Diabetes Devices, Wheelchairs
AdaptHealth Corp, a leading provider of home medical equipment and services, operates a comprehensive platform that caters to the diverse needs of patients with chronic conditions across the United States. Through its subsidiaries, the company delivers a wide range of medical supplies, equipment, and related services, including sleep therapy solutions such as CPAP and bi-PAP services, which are crucial for individuals suffering from obstructive sleep apnea. Additionally, AdaptHealth Corp provides medical devices and supplies for diabetes management, including continuous glucose monitors and insulin pumps, as well as oxygen and chronic therapy services for patients in the comfort of their own homes.
The company's product portfolio is extensive, encompassing wheelchairs, hospital beds, oxygen concentrators, CPAP masks, wound care supplies, diabetes management supplies, orthopedic bracing, breast pumps, and nutritional supplies, among others. This broad range of offerings enables AdaptHealth Corp to support patients with various medical conditions, including those requiring wound care, urological, incontinence, ostomy, and nutritional supplies. By servicing beneficiaries of Medicare, Medicaid, and commercial insurance payors, the company plays a vital role in ensuring that patients have access to the medical equipment and services they need to manage their conditions effectively.
As a key player in the healthcare distribution sector, AdaptHealth Corp is well-positioned to capitalize on the growing demand for home medical equipment and services. With its headquarters in Plymouth Meeting, Pennsylvania, the company is strategically located to serve patients and healthcare providers across the United States. Through its website, https://adapthealth.com, AdaptHealth Corp provides a valuable resource for patients, caregivers, and healthcare professionals seeking information on its products and services. As a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol AHCO, AdaptHealth Corp is committed to delivering value to its shareholders while making a positive impact on the lives of its patients.
Additional Sources for AHCO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
AHCO Stock Overview
Market Cap in USD | 1,282m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Distributors |
IPO / Inception | 2018-05-24 |
AHCO Stock Ratings
Growth 5y | -23.6% |
Fundamental | 6.0% |
Dividend | - |
Rel. Strength Industry | 1820 |
Analysts | 4.22/5 |
Fair Price Momentum | 9.72 USD |
Fair Price DCF | 44.09 USD |
AHCO Dividends
No Dividends PaidAHCO Growth Ratios
Growth Correlation 3m | -55.6% |
Growth Correlation 12m | 21.8% |
Growth Correlation 5y | -72% |
CAGR 5y | -2.06% |
CAGR/Mean DD 5y | -0.04 |
Sharpe Ratio 12m | 0.96 |
Alpha | 37.53 |
Beta | 0.71 |
Volatility | 55.52% |
Current Volume | 1106.4k |
Average Volume 20d | 1657.6k |
As of January 15, 2025, the stock is trading at USD 10.37 with a total of 1,106,448 shares traded.
Over the past week, the price has changed by +8.28%, over one month by +8.17%, over three months by +3.09% and over the past year by +55.34%.
Neither. Based on ValueRay Fundamental Analyses, Adapthealth is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 6.00 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of AHCO as of January 2025 is 9.72. This means that AHCO is currently overvalued and has a potential downside of -6.27%.
Adapthealth has received a consensus analysts rating of 4.22. Therefor, it is recommend to buy AHCO.
- Strong Buy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, AHCO Adapthealth will be worth about 10.5 in January 2026. The stock is currently trading at 10.37. This means that the stock has a potential upside of +1.25%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 11.4 | 9.8% |
Analysts Target Price | 16 | 54.3% |
ValueRay Target Price | 10.5 | 1.3% |